Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant adjunctive therapy in major depressive disorder with inadequate antidepressant response
jRCT2080223660Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Seltorexant + SSRI/SNRI with Placebo + SSRI/SNRI (2 arms). Primary endpoints: Efficacy of seltorexant as adjunctive therapy and Safety and tolerability of seltorexant. Started Sep 2017; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080223660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223660.